首页 | 本学科首页   官方微博 | 高级检索  
检索        


Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
Authors:Chappell William H  Steelman Linda S  Long Jacquelyn M  Kempf Ruth C  Abrams Stephen L  Franklin Richard A  Bäsecke Jörg  Stivala Franca  Donia Marco  Fagone Paolo  Malaponte Graziella  Mazzarino Maria C  Nicoletti Ferdinando  Libra Massimo  Maksimovic-Ivanic Danijela  Mijatovic Sanja  Montalto Giuseppe  Cervello Melchiorre  Laidler Piotr  Milella Michele  Tafuri Agostino  Bonati Antonio  Evangelisti Camilla  Cocco Lucio  Martelli Alberto M  McCubrey James A
Institution:Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, USA.
Abstract:The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Integral components of these pathways, Ras, B-Raf, PI3K, and PTEN are also activated/inactivated by mutations. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of these pathways can contribute to chemotherapeutic drug resistance, proliferation of cancer initiating cells (CICs) and premature aging. This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging. Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways play key roles in the regulation of normal and malignant cell growth. Inhibitors targeting these pathways have many potential uses from suppression of cancer, proliferative diseases as well as aging.
Keywords:Targeted Therapy  Combination Therapy  Drug Resistance  Cancer Stem Cells  Aging  Senescence  Raf  Akt  PI3K  mTOR
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号